Status:
RECRUITING
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
Lead Sponsor:
Istituto Oncologico Veneto IRCCS
Conditions:
Mesothelioma
Mesotheliomas Pleural
Eligibility:
All Genders
18+ years
Brief Summary
Pleural and peritoneal mesotheliomas (PPM) are rare cancers mostly related to asbestos-exposure, which are characterized by a complex histopathological diagnosis and staging, few therapeutic options a...
Eligibility Criteria
Inclusion
- Patients with Mesothelioma of the Pleura and Peritoneum
- Age greater than 18 years of age
- Patients undergoing surgery will require both biopsy and surgical sampling material
- Pathologist's confirmation of the presence of tumor sections in the excised specimens
- Patients in follow-up from active cancer treatment for at least 6 months
Exclusion
- Inadequacy of biological material for analysis under study
- Patients not amenable to active oncologic treatment
- Patients lost to follow-up before 6 months after the end of active oncologic treatment
Key Trial Info
Start Date :
November 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT06581549
Start Date
November 2 2023
End Date
December 31 2026
Last Update
September 5 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico Humanitas
Rozzano, Milano, Italy, 20089
2
Centro di Riferimento Oncologico (CRO) IRCCS
Aviano, Pordenone, Italy, 33081
3
Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo
Alessandria, Italy, 15121
4
Asst Papa Giovanni Xxiii Bergamo
Bergamo, Italy